nach oben

Erschienen in:

01.12.2007 | GENETIC EPIDEMIOLOGY

Genetic polymorphism of CYP2C19 in Maharashtrian population

verfasst von: Yogita Ghodke, Kalpana Joshi, Yashendra Arya, Anjali Radkar, Aditi Chiplunkar, Pooja Shintre, Bhushan Patwardhan

Erschienen in: European Journal of Epidemiology | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Inter-individual variability in drug response is well known. Genetic polymorphism in genes encoding drug-metabolizing enzymes results in variation in drug metabolism and in turn drug response. The cytochrome P450 enzymes (CYP) play a central role in the metabolism of many therapeutic agents. CYP2C19 gene polymorphism is widely studied in Caucasians, African, and Oriental populations; however, far less is known about other ethnic groups such as Indians. Indian population is an inter-mixture of the Aryan, Dravidian, Kolarain, and the Mongoloid races. CYP2C19 gene polymorphism is reported in North Indian and South Indian populations yet not much is known about Maharashtrian population of Australoid-Europoid origin residing in Western India. This is the first report on CYP2C19 allele and genotype frequencies in Maharashtrian population. In this study, genotypes of major allelic variants of CYP2C19 gene in 139 unrelated healthy Maharashtrian subjects was determined and their frequencies were compared with previously studied Indian and other populations. Meta-analysis revealed that the study population is distinct from Caucasians, Africans and some of the Asian populations and significant heterogeneity exists among Indian subpopulations.

Evans WE. Pharmacogenomics: marshalling the human genome to individualize drug therapy. Gut 2003;52 Suppl II:ii10–8.

Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–49.PubMedCrossRef

Meyer UA. Pharmacogenetics. The slow, the rapid and the ultrarapid. Proc Natl Acad Sci USA 1994;91:1983–4.PubMedCrossRef

Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285–99.PubMedCrossRef

Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995;73:539–53.PubMedCrossRef

de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419–22.PubMed

de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol pharmacol 1994;96:594–8.

Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’ hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661–6.PubMedCrossRef

Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533–7.PubMedCrossRef

10.

Xiao ZS, Golstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH. Differences in the incidence of CYP2C19 polymorphism affecting the S-mephenyotin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604–9.PubMed

11.

Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Shin J-G, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160–9.PubMedCrossRef

12.

Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997;349:921–2.PubMedCrossRef

13.

Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388–97.PubMedCrossRef

14.

Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther 2000;68:328–35.PubMedCrossRef

15.

Rosemary J, Adithan C, Soya S, Gerard N, Chanolean S, Abraham B, Satyanarayanamoorthy K, Peter A, Rajagopal K. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in south Indian population. Fundam Clin Pharmacol 2005;19(1):101–5.CrossRef

16.

Karve I. ‘Maharashtra-Land & it’s people’ Maharashtra State gazetteers general series. Maharashtra State: Bombay Directorate of Government Printing, Stationary & publications; 1968.

17.

Miller SA, Dykes DD. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16(3):1215.PubMedCrossRef

18.

Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in Mephenytoin metabolism. Methods enzymol 1996;272:210–7.PubMedCrossRef

19.

Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53–76.PubMedCrossRef

20.

Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation: current state of the knowledge of cytochrome P450 (CYP)2D6 and 2C19. Clin Pharmacokinet 1995;29:192–209.PubMed

21.

Ruas JC, Lechner MC. Allele frequency of CYP2C19 in a Portoguese population. Pharmacogenetics 1997;7:333–5.PubMedCrossRef

22.

Kaisary A, Smith P, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488–93.PubMed

23.

Tsuneoka Y, Fukushima K, Matsu Y, Ichikwa Y, Watanabe Y. Genetic analysis of the CYP2C19 gene in the Japanese population. Life Sci 1996;59:1711–15.PubMedCrossRef

24.

May DG, Black CM, Olsen NJ, et al. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquine, and mephenytoin. Clin Pharmacol Ther 1990;48:286–95.PubMedCrossRef

25.

Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994;56:398–405.PubMedCrossRef

26.

Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5(6):358–63.PubMedCrossRef

27.

Futura T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027–30.

28.

Wan J, Xia H, He N, et al. The elimination of diazepam in Chinese subjects is dependant on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996;42:471–4.PubMedCrossRef

29.

Qin XP, Xie HG, Wang W, et al. Effect of gene dosage of Cgamma19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999;66:642–6.PubMed

30.

Sogawa K, Gotoh O, Kawajiri K, et al. Complete nucleotide sequence of a methylcholanthrene-inducible cytochrome pP-450 (P-450d) gene in rat. J Biol Chem 1985;260:5026–31.PubMed

31.

Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609–16.PubMed

32.

Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2002;53(4):408–9.CrossRef

33.

Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation by human liver microsomes is mediated by CYP3Aisoforms as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994;37:413–20.PubMed

34.

Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jallion P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the experiments. J Pharmacol Exp Ther 1997;280:730–8.PubMed

35.

Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999;48(3):402–8.PubMedCrossRef

36.

Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001;36:669–72.PubMedCrossRef

37.

Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (s)-mephenytoin could be identified by haplotypes of CYP2C19 in japanese. Pharmacogenetics 1996;36:669–72.

38.

Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype in determined by omeprazole in a Korean population. Pharmacogentics 1996;6:547–51.CrossRef

39.

Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Bangchange K, Tawalee A, Krikreangsak N, Cykleng U, Tassaneeyakul W. CYP2C19 Genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet 2006;21(4):286–90.PubMedCrossRef

40.

Yang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol 2004;58(3):332–5.PubMedCrossRef

41.

Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7(1):59–64.PubMedCrossRef

42.

Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp SO, Roots I, Brockmöller J. Low frequencyof defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185–92.PubMed

43.

Sviri S, Shpizen S, et al. Phenotypic—genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 1999;65:275–82.PubMedCrossRef

44.

Kaneko A, Lum JK, Yaviong L, Takahashi N, Ishizaki T, Bertilsson L, Kobayakawa T, Bjorkman A. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999;9(5):581–90.PubMedCrossRef

45.

Griese EU, Ilett KF, Kitteringham NR, et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia. Pharmacogenetics 2001;11:69–76.PubMedCrossRef

46.

Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59(4):30312.CrossRef

47.

Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Eur J Clin Pharmacol 2003;59(4):303–12.CrossRef

48.

Bo_ina N, Graniæ P, Laliæ Z, Tramišak I, Lovriæ M, Stavljeniæ-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian Population. Roatian Med J 2003;44(4):425–8.

49.

Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003;56:653–657.PubMedCrossRef

50.

Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics 1997;7:333–5.PubMedCrossRef

51.

Nowak MP, Sellers EM, Tyndale RF. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther 1998;64:378–83.PubMedCrossRef

52.

Bravo-Villalta H, Yamamoto K, Nakamura K, Baya A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 2005;61:179–84.PubMedCrossRef

53.

Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Pa´ l Weihe Lundgren S, Lundblad MS, Brøsen K. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005;61:491–97.PubMedCrossRef

54.

Yamada H, Dahl M-L, Lannfelt L, Viitanen M, Winblad B, SjoÈ qvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998;54:479–81.PubMedCrossRef

55.

Bathum L, Andersen-Ranberg K, Boldsen J, Brùsen K, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427–30.PubMedCrossRef

56.

Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999;48(3):402–8.PubMedCrossRef

57.

Hamdy SI, Hiratsuka M, Narahara K, Enany M, Moursi N, Ahmed MS, Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596–603.PubMedCrossRef

58.

Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521–6.PubMedCrossRef

59.

Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998;64(4):391–401.PubMedCrossRef

60.

Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population in Zimbabwe. Clin Pharmacol Ther 1995;57:656–1.PubMedCrossRef

61.

Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6, CYP2C19 in East, Southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001;75:11–7.CrossRef

Titel: Genetic polymorphism of CYP2C19 in Maharashtrian population
verfasst von: Yogita Ghodke
Kalpana Joshi
Yashendra Arya
Anjali Radkar
Aditi Chiplunkar
Pooja Shintre
Bhushan Patwardhan
Publikationsdatum: 01.12.2007
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 12/2007
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-007-9196-0

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

Feasibility of recruiting a birth cohort through the Internet: the experience of the NINFEA cohort

Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly study

The Generation R Study Biobank: a resource for epidemiological studies in children and their parents

Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe

Gender difference on the development of metabolic syndrome: a population-based study in Taiwan

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases